ArticleBJR artificial intelligence2026
Predictive deep learning model based on contrast-enhanced mammography for breast cancer diagnosis: a pilot study.
Article in BJR artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The interpretation of contrast-enhanced mammography (CEM) images heavily depends on radiologists' expertise, highlighting the need for automated tools to assist clinical decision-making. This pilot study aimed to develop a deep learning model using CEM images to predict the histological diagnosis of breast cancer. Methods: We retrospectively analyzed patients who underwent CEM followed by histopathological assessment (October 2022-May 2023) across 2 centers. CEM images from center 1 were used for model development, including training and 10-fold cross-validation, while images from center 2 served as an independent external test set. The breast region was manually segmented, and 2 deep learning architectures were implemented as ensemble classifiers, using biopsy results as reference standard. Performance metrics included accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the Receiver Operating Characteristic Curve (ROC) curve (AUC). Results: A total of 106 CEM images were retrospectively analyzed (50 from center 1 and 56 from center 2), obtained using different mammography systems. Histopathology identified 51 lesions (48%) as malignant and 55 (52%) as benign. Cross-validation yielded an ROC-AUC of 75% [58.4-91.6], accuracy of 68.7% [58.3-79], sensitivity of 68.9% [52.2-85.6], specificity of 67.8% [65.4-70.2], PPV of 69.3% [55.5-83.1], and NPV of 73.5% [55.2-91.8] ( Conclusions: The study showed promising performance but requires further development and dataset expansion. The model has the potential to be integrated into clinical practice. Advances in knowledge: A deep learning model based on CEM provides a tool to support physicians in the decision-making process and reduce invasiveness in breast cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.